Document is current
Any future updates will be listed below
-
Authors
Lee, Yong-ho https://orcid.org/0000-0002-6219-4942
Lim, Soo https://orcid.org/0000-0002-4137-1671
Davies, Melanie J. https://orcid.org/0000-0002-9987-9371
- License Information
-
More Information
Article History
Accepted: 8 August 2025
First Online: 11 September 2025
Competing interests
: Y.L. has received research grants from Asen, Chong Kun Dang Pharmaceutical, Daewoong Pharmaceutical, Jeil Pharmaceutical and Yuhan Corporation; and clinical investigator fees from Eli Lilly, Hanmi Pharmaceutical and Novo Nordisk. S.L. has received research grants from LG Chem, Merck Sharp & Dohme and Novo Nordisk, and honoraria as a consultant or speaker from Abbott, AstraZeneca, Boehringer Ingelheim, Chong Kun Dang Pharmaceutical, Daewoong Pharmaceutical, LG Chem and Novo Nordisk. M.J.D. has acted as consultant, advisory board member and speaker for Boehringer Ingelheim, Lilly, Novo Nordisk and Sanofi; has been an advisory board member and speaker for AstraZeneca; has acted as an advisory board member for Janssen, Lexicon, Pfizer and ShouTi Pharma; has acted as a speaker for Napp Pharmaceuticals, Novartis and Takeda Pharmaceuticals International; and has received grants in support of investigator-initiated trials from AstraZeneca, Boehringer Ingelheim, Lilly, Janssen, Novo Nordisk and Sanofi-Aventis.
